Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
42 hedge funds and large institutions have $196M invested in Biora Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 21 closing their positions.
45% more call options, than puts
Call options by funds: $935K | Put options by funds: $643K
4% less capital invested
Capital invested by funds: $206M → $196M (-$9.11M)
11% less funds holding
Funds holding: 47 → 42 (-5)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
24% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 21
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Athyrium Capital Management
New York
|
+$28.6M |
| 2 |
AC
Armistice Capital
New York
|
+$15.2M |
| 3 |
PGM
Parian Global Management
Pound Ridge,
New York
|
+$4.09M |
| 4 |
D.E. Shaw & Co
New York
|
+$740K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$460K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$8.32M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.16M |
| 3 |
FAM
Fred Alger Management
New York
|
-$2.29M |
| 4 |
BlackRock
New York
|
-$2.26M |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$1.92M |
BIOR Hedge Fund Activity: Q2 2021 in Review
42 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q2 2021, worth a combined $196M — down 4.4% from $206M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BIOR and 16 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Athyrium Capital Management, adding an estimated $28.6M. The largest seller was Altium Capital Management, exiting entirely with an estimated $8.32M sold.
- 42 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q2 2021, down from 47 in Q1 2021.
- Funds reported $196M of Biora Therapeutics, Inc. Common Stock stock for Q2 2021, down 4.4% quarter-over-quarter.
- 16 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q2 2021 and 21 closed out, a net change of -5 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q2 2021 was Athyrium Capital Management, an estimated $28.6M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q2 2021 was Altium Capital Management, an estimated $8.32M sold.
Based on aggregated 13F filings for Q2 2021.